MabVax Therapeutics Holdings, Inc. announced the appointment of Jeffrey Eisenberg to the board of directors. Jeffrey Eisenberg served in a variety of senior management positions, including most recently as President, Chief Executive Officer and a board member of Noven Pharmaceuticals, Inc.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | +10.05% | +182.21% |
2020 | MabVax Therapeutics Holdings, Inc. Went Out of Business | CI |
2020 | Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+182.21% | 213K | |
+9.27% | 114B | |
+11.40% | 104B | |
-13.84% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.10% | 17.89B | |
+7.67% | 14.28B | |
+34.44% | 12.55B |
- Stock Market
- Equities
- MBVXQ Stock
- News MabVax Therapeutics Holdings, Inc.
- MabVax Therapeutics Holdings, Inc. Appoints Jeffrey Eisenberg as Director